Abstract

Chronic obstructive pulmonary disease (COPD) is a prevalent chronic disease of the upper airways and it is the fourth cause of death in the Polish population. COPD is characterized by not fully reversible constriction of air flow, which is a consequence of inflammation caused by noxious fumes and gases, particularly tobacco smoke. It seems that among mediators of inflammation, chemokine CXCL8 (interleukin 8) may play a pivotal role. CXCL8 is a member of the chemokine family and is a major chemoattractant to neutrophils, which are responsible for inducing and sustaining the inflammatory state. It was shown that there is a correlation between the number of neutrophils in induced sputum in COPD patients, the CXCL8 level, and clinical outcome of the illness. Increased frequency of exacerbation may be a result of increased secretion of mucus caused by increased expression of genes encoding mucins (MUC5AC and MUCB), which is stimulated by high levels of CXCL8. Activation of the CXCL8‑encoding gene depends on pro‑inflammatory cytokines such as tumor necrosis factor, interleukin 1 and lipopolysaccharide which activate transcription factor NF‑κB. Inhibitors of CXCL8 (such as N‑acetyl‑L‑cysteine) cause a decrease of exacerbation frequency and clinical symptoms. The data presented in the review suggest that CXCL8 plays a major role in the inflammatory process leading to COPD.

References

• 1. Adcock I.M., Lane S.J.: Mechanisms of steroid action and resistancein inflammation. Corticosteroid‑insensitive asthma: molecularmechanisms. J. Endocrinol., 2003; 178: 347‑355
  Google Scholar
• 2. Baggiolini M.: Chemokines in pathology and medicine. J. Intern.Med., 2001; 250: 91‑104
  Google Scholar
• 3. Barnes P.J.: Chronic obstructive pulmonary disease. N. Engl. J.Med., 2000; 343: 269‑280
  Google Scholar
• 4. Barnes P.J.: Mediators of chronic obstructive pulmonary disease.Pharmacol. Rev., 2004; 56: 515‑548
  Google Scholar
• 5. Barnes P.J.: The cytokine network in asthma and chronic obstructivepulmonary disease. J. Clin. Invest., 2008; 118: 3546‑3556
  Google Scholar
• 6. Barnes P.J., Adcock I.M.: Chronic obstructive pulmonary diseaseand lung cancer: a lethal association. Am. J. Respir. Crit. Care Med.,2011; 184: 866‑867
  Google Scholar
• 7. Barnes P.J., Shapiro S.D., Pauwels R.A.: Chronic obstructive pulmonarydisease: molecular and cellular mechanism. Eur. Respir. J.,2003; 22: 672‑688
  Google Scholar
• 8. Batura‑Gabryel H.: Zmiany ogólnoustrojowe u chorych na przewlekłąobturacyjną chorobę płuc. Pneumonol. Alergol. Pol., 2009;77: 180‑185
  Google Scholar
• 9. Batura‑Gabryel H.: POChP jako choroba systemowa. Terapia,2010; 9: 6‑11
  Google Scholar
• 10. Batura‑Gabryel H.: Biomarkery w POChP – czy są nam potrzebne.Pneumonol. Alergol. Pol., 2011; 79: 144‑150
  Google Scholar
• 11. Bautista M.V., Chen Y., Ivanova V.S., Rahimi M.K., Watson A.M.,Rose M.C.: IL‑8 regulates mucin gene expression at the posttrancriptionallevel in lung epithelial cells. J. Immunol., 2009; 183: 2159‑2166
  Google Scholar
• 12. Bednarek M.: Zespół nakładania przewlekłej obturacyjnej chorobypłuc i obturacyjnego bezdechu sennego. Pneumonol. Alergol.Pol., 2011; 79: 67‑69
  Google Scholar
• 13. Bhowmik A., Seemungal T.A., Sapsford R.J., Wedzicha J.A.: Relationof sputum inflammatory markers to symptoms and lung functionchanges in COPD exacerbations. Thorax, 2000; 55: 114‑120
  Google Scholar
• 14. Blanc P.D., Menezes A.M., Plana E., Mannino D.M., Hallal P.C., TorenK., Eisner M.D., Zock J.P.: Occupational exposures and COPD: anecologicalanalysis of international data. Eur. Respir. J., 2009; 33: 298‑304
  Google Scholar
• 15. Chazan R.: Nowe leki w przewlekłej obturacyjnej chorobie płuc.Pneumonol. Alergol. Pol., 2011; 79: 232‑238
  Google Scholar
• 16. Chazan R.: Nowe możliwości terapeutyczne w POChP. Pneumonol.Alergol. Pol., 2013; 81: 154‑161
  Google Scholar
• 17. Chorostowska‑Wynimko J., Domagała‑Kulawik J., Fijałkowska A.,Korzeniewska Koseła M., Kuca P., Radzikowska E., Szturmowicz M.:Nowości z Kongresu ERS w Barcelonie, 18‑22 września 2010 (cz.I).Pneumonol. Alergol. Pol., 2011; 79: 151‑164
  Google Scholar
• 18. Chung K.F.: Cytokines in chronic obstructive pulmonary disease.Eur. Respir J., 2001; 18: 50‑59
  Google Scholar
• 19. Durham A.L., McLaren A., Hayes B.P., Caramori G., Clayton C.L.,Barnes P.J., Chung K.F., Adcock I.M.: Regulation of Wnt4 in chronicobstructive pulmonary disease. FASEB J., 2013; 27: 2367‑2381
  Google Scholar
• 20. Feng E., Wan R., Yang S., Yan Z., Wang S., He W., Zhang Y., Yin H.,Chen Z., Liu R.: Expression levels of induced sputum IL‑8 and IL‑10and drug intervention effects in patients with acute exacerbatedCOPD complicated with chronic corpulmonale at high altitude. Exp.Ther. Med., 2013; 6: 747‑752
  Google Scholar
• 21. Gilmour P.S., Rahman I., Hayashi S., Hogg J.C., Donaldson K., MacneeW.: Adenoviral E1A primes alveolar epithelial cells to PM10‑inducedtranscription of interleukin‑8. Am. J. Physiol. Lung Cell. Mol.Physiol., 2001; 281: L598‑L606
  Google Scholar
• 22. Górecka D., Jassem E., Pierzchała W., Śliwiński P.: Zalecenia PolskiegoTowarzystwa Chorób Płuc dotyczące rozpoznawania i leczeniaprzewlekłej obturacyjnej choroby płuc (POChP). Pneumonol.Alergol. Pol., 2012; 80: 220‑254
  Google Scholar
• 23. Górecka D., Puścińska E.: Profilaktyka przewlekłej obturacyjnejchoroby płuc. Pneumonol. Alergol. Pol., 2011; 79: 239‑245
  Google Scholar
• 24. Grodecka M., Waśniowska K.: Interceptory ‑ „ciche” receptorychemokin. Postępy Hig. Med. Dośw., 2007; 61: 231‑239
  Google Scholar
• 25. Hornikx M., Van Remoortel H., Lehouck A., Mathieu C., Maes K.,Gayan‑Ramirez G., Decramer M., Troosters T., Janssens W.: Vitamin Dsupplementation during rehabilitation in COPD: a secondary analysisof a randomized trial. Respir. Res., 2012; 13: 84‑92
  Google Scholar
• 26. Jackson P.L., Noerager B.D., Jablonsky M.J., Hardison M.T., CoxB.D., Patterson J.C., Dhanapal B., Blalock J.E., Muccio D.D.: A CXCL8receptor antagonist based on the structure of N‑acetyl‑proline‑glycine‑proline.Eur. J. Pharmacol., 2011; 668: 435‑442
  Google Scholar
• 27. Jeffery P.K.: The roles of leukotrienes and the effects of leukotrienereceptor antagonists in the inflammatory response andremodeling of allergic asthma. Clin. Exp. Allergy, 2001; 1: 148‑153
  Google Scholar
• 28. Kałuska K., Ziora D.: Remodeling dróg oddechowych w astmieoskrzelowej i POChP cz.I. Zmiany strukturalne w oskrzelach. AlergiaAstma Immunologia, 2005; 10: 109‑115
  Google Scholar
• 29. Kaur M., Singh D.: Neutrophil chemotaxis caused by chronicobstructive pulmonary disease alveolar macrophages: the role ofCXCL8 and the receptors CXCR1/CXCR2. J. Pharmacol. Exp. Ther.,2013; 347: 173‑180
  Google Scholar
• 30. Knight D.: Epithelium–fibroblast interactions in response toairway inflammation. Immunol. Cell Biol., 2001; 79: 160‑164
  Google Scholar
• 31. Knobloch J., Wahl C., Feldmann M., Jungck D., Strauch J., StoelbenE., Koch A.: Resveratrol attenuates the release of inflammatorycytokines from human bronchial smooth muscle cells exposed tolipoteichoic acid in chronic obstructive pulmonary disease. BasicClin. Pharmacol. Toxicol., 2014; 2: 202‑209
  Google Scholar
• 32. Król M., Kraus‑Filarska M., Obojski A.: Patogeneza przewlekłejobturacyjnej choroby płuc – udział komórek i cytokin w procesiezapalnym. Adv. Clin. Exp. Med., 2007; 16: 277‑285
  Google Scholar
• 33. Lange N.E., Sparrow D., Vokonas P., Litonjua A.A.: Vitamin D deficiency,smoking and lung function in the normative aging study.Am. J. Respir. Crit. Care Med., 2012; 186: 616‑621
  Google Scholar
• 34. Li J., Kartha S., Iasvovskaia S., Tan A., Bhat R.K., Manaligod J.M.,Page K., Brasier A.R., Hershenson M.B.: Regulation of human airwayepithelial cell IL‑8 expression by MAP kinases. Am. J. Physiol. LungCell Mol. Physiol., 2002; 283: L690‑L699
  Google Scholar
• 35. Mata M., Morcillo E., Gimeno C., Cortijo J.: N‑acetyl‑L‑cysteine(NAC) inhibit mucin synthesis and pro‑inflammatory mediators inalveolar type II epithelial cells infected with influenza virus A andB and with respiratory syncytial virus (RSV). Biochem. Pharmacol.,2011; 82: 548‑555
  Google Scholar
• 36. Moon H.G., Zheng Y., An C.H., Kim Y.K., Jin Y.: CCN1 secretioninduced by cigarette smoking extracts augments IL‑8 release frombronchial epithelial cells. PLoS One, 2013; 8: e.68199
  Google Scholar
• 37. Mortaz E., Adcock I.M., Ito K., Kraneveld A.D., Nijkamp F.P., FolkertsG.: Cigarette smoke induces CXCL8 production by human neutrophils viaactivation of TLR9 receptor. Eur. Respir. J., 2010; 36: 1143‑1154
  Google Scholar
• 38. Mortaz E., Henricks P.A., Kraneveld A.D., Givi M.E., Garssen J.,Folkerts G.: Cigarette smoke induces the release of CXCL‑8 frombronchial epithelial cells via TLRs and induction of the inflammasone.Biochim. Biophys. Acta, 2011; 1812: 1104‑1110
  Google Scholar
• 39. Mróz R., Skopiński T., Hołownia A., Chyczewska E., Braszko J.J.:Leczenie przewlekłej obturacyjnej choroby płuc – bronchodylatacja i przeciwzapalna farmakoterapia celowana. Pneumonol. Alergol.Pol., 2011; 79: 32‑38
  Google Scholar
• 40. Mróz R.M., Szulakowski P., Pierzchała W., Chyczewska E., MacNeeW.: Patogeneza przewlekłej obturacyjnej choroby płuc. Część I.Podłoże komórkowe. Wiad. Lek., 2006; 59: 92–96
  Google Scholar
• 41. Nadigel J., Audusseau S., Baglole C.J., Eidelman D.H., HamidQ.: IL‑8 production in response to cigarette smoke is decreasedin epithelial cells from COPD patients. Pulm. Pharmacol. Ther.,2013; 5: 596‑602
  Google Scholar
• 42. OMIM. www.ncbi.nlm.nih.gov/omim/(19.05.2014)
  Google Scholar
• 43. Overbeek S.A., Henricks P.A., Srienc A.I., Koelink P.J., de KruijfP., Lim H.D., Smit M.J., Zaman G.J., Garssen J., Nijkamp F.P., KraneveldA.D., Folkerts G.: N‑acetylated Proline‑Glycine‑Proline inducedG‑protein dependent chemotaxis of neutrophils is independent ofCXCL8 release. Eur. J. Pharmacol., 2011; 668: 428‑434
  Google Scholar
• 44. Overbeek S.A., Kleinjan M., Henricks P.A., Kamp V.M., RicciardoloF.L., Georgiou N.A., Garssen J., Kraneveld A.D., Folkerts G.: Chemo‑attractantN‑acetyl proline‑glycine‑proline induces CD11b/CD18‑dependentneutrophil adhesion. Biochim. Biophys. Acta., 2013; 1830:2188‑2193
  Google Scholar
• 45. Panzner P.: Cytokiny w przewlekłej obturacyjnej chorobie płucoraz przewlekłym zapaleniu oskrzeli. Alergia Astma Immunologia,2002; 7: 91‑99
  Google Scholar
• 46. Paplińska‑Goryca M., Nejman‑Gryz P., Chazan R., Grubek‑JaworskaH.: The expression of the eotaxins IL‑6 and CXCL8 in humanepithelial cells from various levels of the respiratory tract. Cell Mol.Biol. Lett., 2013; 18: 612‑630
  Google Scholar
• 47. Passowicz‑Muszyńska E., Gostkowska‑Malec A., Jankowska R.,Piesiak P.: Przewlekła obturacyjna choroba płuc a choroby układusercowo‑naczyniowego. Pneumonol. Alergol. Pol., 2010; 1: 28‑32
  Google Scholar
• 48. Pierzchała W., Barczyk A., Górecka D., Śliwiński P., Zieliński J.:Zalecenia Polskiego Towarzystwa Chorób Płuc rozpoznawania i leczeniaprzewlekłej obturacyjnej choroby płuc (POChP). Pneumonol.Alergol. Pol., 2010; 78: 318‑347
  Google Scholar
• 49. Powrie D.J., Wilkinson T.M., Donaldson G.C., Jones P., ScrineK., Viel K., Kesten S., Wedzicha J.A.: Effect of tiotropium on sputumand serum inflammatory markers and exacerbations in COPD. Eur.Respir. J., 2007; 3: 472‑478
  Google Scholar
• 50. Prescott E., Bjerg A.M., Andersen P.K., Lange P., Vestbo J.:Gender difference in smoking effects on lung function and risk ofhospitalization for COPD: results from Danish longitudinal populationstudy. Eur. Respir. J., 1997; 10: 822‑827
  Google Scholar
• 51. Rennard S.I.: Pathogenesis of chronic obstructive pulmonarydisease. Pneumonol. Alergol. Pol., 2011; 79: 132‑138
  Google Scholar
• 52. Rocznik demograficzny 2010. Główny Urząd Statystyczny, 2011
  Google Scholar
• 53. Rollins B.: Chemokines. Blood, 1997; 90: 909‑928
  Google Scholar
• 54. Sin D., Vestbo J.: Biomarkers in chronic obstructive pulmonarydisease. Amer. Thorac. Soc., 2009; 6: 543‑545
  Google Scholar
• 55. Singh D., Edwards L., Tal‑Singer R., Rennard S.: Sputum neutrophilsas a biomarker in COPD: findings from the ECLIPSE study.Respir. Res., 2010; 11: 77‑89
  Google Scholar
• 56. Snelgrove R.J.: Targeting of a common receptor shared byCXCL8 and N‑Ac‑PGP as a therapeutic strategy to alleviate chronicneutrophilic lung diseases. Eur. J. Pharmacol., 2011; 667: 1‑3
  Google Scholar
• 57. Stein B., Baldwin A.S Jr.: Distinct mechanisms for regulation ofthe interleukin‑8 gene involve synergism and cooperativity betweenC/EBP and NF‑kappa B. Mol. Cell Biol., 1993; 11: 7191‑7198
  Google Scholar
• 58. Stoller J.K., Aboussouan L.S.: A review of a1‑antitrypsin deficiency.Am. J. Respir. Crit. Care Med., 2012; 185: 246‑259
  Google Scholar
• 59. Strieter R.M.: Interleukin‑8: a very import ant chemokine of thehuman airway epithelium. Am. J. Physiol. Lung Cell Mol. Physiol.,2002; 283: L688‑L689
  Google Scholar
• 60. Szczegielniak J., Bogacz K., Łuniewski J., Majorczyk E., TukiendorfA., Czerwiński M.: Wpływ fizjoterapii na stężenie interleukiny‑8u chorych na przewlekłą obturacyjną chorobę płuc. Pneumonol.Alergol. Pol., 2011; 79: 184‑188
  Google Scholar
• 61. Śliwiński P.: Współistnienie astmy i POChP. Alergia, 2009; 2: 13‑18
  Google Scholar
• 62. Van Damme J., Mantovani A.: Editorial. From cytokines to chemokines.Cytokine Growth Factor Rev., 2005; 6: 549‑551
  Google Scholar
• 63. Waschki B., Kirsten A., Holz O., Müller K.C., Meyer T., Watz H.,Magnussen H.: Physical activity is the strongest predictor of all‑causemortality in patients with COPD: a prospective cohort study. Chest,2011; 140: 331‑342
  Google Scholar
• 64. Waśniowska K.: Chemokiny – perspektywy zastosowania związkówblokujących ich działanie w terapii. Postępy Hig. Med. Dośw.,2004; 58: 37‑46
  Google Scholar

Full text